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Abstract
Background: Parotid surgery is a common ear, nose, and throat procedure. Facial nerve paralysis is the main feared
complication following this surgery. To avoid this paralysis, intraoperative facial nerve monitoring is often used, but
neuromuscular blocking agents interfere with this technique. Therefore, the neuromuscular blocking agent used should
have a short duration of muscle relaxation. With the discovery of sugammadex, a steroidal neuromuscular blocking agent
has acquired the potential to be used in place of succinylcholine.
Case presentation: A 41-year-old African woman was scheduled for a parotidectomy at our hospital. Rocuronium-induced
neuromuscular block was reversed intraoperatively with sugammadex to facilitate identification of facial nerve
function. The facial nerve was identified without incident, and surgical conditions were good for the removal of
the tumor. During postoperative follow-up, no evidence of residual paralysis has been noted.
Conclusions: In parotid surgery, the use of sugammadex allows free use of a steroidal neuromuscular blocking
agent for intubation and thus intraoperative facial nerve monitoring can be done safely.
Keywords: Parotid surgery, Neuromuscular blocking agents, Intubation, Sugammadex, Intraoperative facial nerve
monitoring, Case report
Background
Parotid surgery is a common ear, nose, and throat proced-
ure. Transient or permanent facial nerve paralysis during
this operation is still the most feared complication [1].
Intraoperative use of nerve integrity monitors during par-
otid surgery has been advocated to reduce the incidence of
facial nerve paralysis, but neuromuscular blocking agents
(NMBAs) interfere with the use of this technique. There-
fore, the NMBA used should induce a short duration of
muscle relaxation. Previously, the choice was limited to
succinylcholine, which has some undesirable side effects,
such as the risk of anaphylaxis, increased serum potassium
levels, and other cardiovascular complications [2, 3]. The
use of an anesthetic protocol without muscle relaxants
might be responsible for difficult intubation, hemodynamic
changes, and laryngeal complications.
With the discovery of sugammadex, steroidal NMBA
has acquired the potential to be used in place of suc-
cinylcholine in parotid surgery with intraoperative facial
nerve monitoring (IFNM). The use of sugammadex
could allow better intubating conditions with better intra-
operative identification of facial nerves, especially where
contraindications to succinylcholine such as hyperkalemia,
exist. This is the second report in the literature of parotid
surgery in which rocuronium was administered and later
antagonized with sugammadex for IFNM.
Case presentation
A 41-year-old African woman weighing 72 kg and 169 cm
tall, with American Society of Anesthesiologists physical
status class I, was referred to our hospital because of
tumefaction of the neck. Her clinical examination revealed
an isolated parotid mass without associated lymphadenop-
athy. She had no pain or peripheral facial nerve palsy. The
magnetic resonance imaging results were in favor of a
pleomorphic adenoma (Figs. 1 and 2), and the patient was
scheduled for a parotidectomy with general anesthesia.
The results of the patient’s cardiovascular examination
were normal, with a noninvasive blood pressure of 131/71
mmHg and a heart rate of 79 beats/minute. Her respira-
tory examination revealed no dyspnea or snoring. Her
oxygen saturation was 98 % on room air. An examination
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of her upper airway demonstrated good opening of the
mouth and good mobility of the cervical spine (Mallam-
pati class I). Her laboratory test results were a urea plasma
concentration of 0.18 g/L, a creatinine level of 6 mg/L,
blood glucose level of 0.99 mg/dl, hemoglobin concen-
tration of 15.1 g/dl, platelet count of 213,000/mm3,
prothrombin time of 12.9 seconds, and international
normalized ratio of 1.2. Her chest x-ray and electrocar-
diogram (ECG) were unremarkable.
After written informed consent was obtained from the
patient, it was decided to use general anesthesia during
the procedure. Upon the patient’s arrival in the operating
theater, intravenous access was established and standard
anesthesia monitoring (three-lead ECG, peripheral oxygen
saturation, noninvasive blood pressure) was instituted.
Neuromuscular monitoring was performed using accel-
eromyography. Following calibration, the ulnar nerve was
supramaximally stimulated with a square pulse of 0.2-ms
duration delivered as train-of-four (TOF) pulses at in-
tervals of 15 seconds. The resulting contractions of the
adductor pollicis muscles were quantified by using an
acceleromyographic monitor (Infinity® Trident® NMT
SmartPod®; Dräger, Lübeck, Germany). The TOF ratio
and time interval from injection of the reversal agent to
TOF ratio 0.9 were recorded.
Before induction of anesthesia, midazolam 2 mg was
administered intravenously as premedication. After 5
minutes of adequate preoxygenation, anesthesia was ini-
tiated with fentanyl (2.5 μg/kg) and propofol (3 mg/kg)
without significant hemodynamic changes. To facilitate
tracheal intubation, rocuronium (0.5 mg/kg) was admin-
istered after effective mask ventilation. Once there was
no twitching in response to TOF stimulation (1 minute,
45 seconds), the patient’s airway was successfully secured
after the first attempt with a 7.0-mm endotracheal tube.
The endotracheal tube was connected to a closed “low-
flow” anesthetic breathing circuit. Ventilation was con-
trolled to maintain normocapnia with a tidal volume of
8 ml/kg, a respiratory rate of 12 breaths/minute, and
peak inspiratory pressure of 20 cmH2O. Anesthesia was
maintained with isoflurane (1 %) in a mixture of oxygen
and nitrous oxide (50 %:50 %). The end-tidal concentra-
tions of anesthetic and carbon dioxide were measured
continuously using a multiple gas monitor. The depth of
anesthesia was monitored by bispectral index (BIS), and
body temperature was maintained using heating blan-
kets. The patient was placed in supine position and with
slight Trendelenburg tilting of the table and the patient’s
head turned to the left side. A bolus dose of fentanyl
was administered before starting the skin incision to
maintain a BIS score between 40 and 60. After the surgi-
cal incision was made (15 minutes after induction), there
was no response on the basis of TOF ratio. Neuromuscu-
lar block was reversed with sugammadex (4 mg/kg). The
TOF reached 0.9 after 5 minutes. No hemodynamic or re-
spiratory changes were noted. We stopped the neuromus-
cular transmission (NMT) monitoring after obtaining a
TOF ratio above 0.9 in three consecutive measurements.
The inspired isoflurane concentration was gradually
increased to 1.8 % to prevent movement during critical
phases of the surgical procedure after reversing neuro-
muscular blockade. The parotid gland was carefully dis-
sected under magnification with facial nerve monitoring.
The facial nerve was identified using the NIM 2.4 nerve
integrity monitoring system (MEDTRONIC-XOMED,
Fig. 1 Axial T1-weighted image with hypointensity showing the
tumor process of the right parotid gland
Fig. 2 Coronal enhancement after gadolinium injection
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Jacksonville, FL, USA), and after 1 h surgical conditions
were good for the removal of the tumor.
The patient was extubated when fully awake after a
smooth emergence from anesthesia. Her oxygen satur-
ation was 99 % with 2 L/minute of supplemental oxygen.
Her postoperative course was uneventful, and no evidence
of facial nerve paralysis was noted in the postinterven-
tional surveillance room. The patient was discharged to
home after 5 days of hospitalization.
Discussion
Facial nerve palsy remains a serious complication after
parotid surgery [1, 4]. It is feared by the surgical team
and has a negative emotional and functional impact on
the patient. The incidence of temporary facial nerve dys-
function may be quite high, with some authors reporting
occurrence in up to 76 % of patients. Permanent facial
nerve paralysis occurs much less frequently; some au-
thors have reported rates of approximately 4–5 % [5, 6].
Risk factors for facial nerve injury include advanced
age, inflammatory diseases of the parotid gland, dur-
ation of surgery, revision surgery, extent of surgery, and
malignancy [5, 7–9].
Positive identification and preservation of the facial
nerve is the key to preventing inadvertent facial nerve
injury. IFNM has been advocated to reduce the inci-
dence of facial nerve paralysis in parotid surgery. The
technique is used for assessing the anatomic and func-
tional integrity of nerves during parotid surgery and can
be valuable in the presence of a high risk of nerve injury.
This method requires intact NMT. However, the value
of the procedure may be limited by the administration of
NMBAs, which are required to prevent tracheal and/or
laryngeal damage, difficult intubation, and hemodynamic
changes during endotracheal intubation [10, 11]. To
minimize the effect of this neuromuscular blockade,
short-acting NMBAs such as succinylcholine and rocur-
onium were used. Succinylcholine has some undesirable
side effects, such as the risk of anaphylaxis, increased
serum potassium levels, and other cardiovascular com-
plications [2, 3].
An alternative method is to use a nondepolarizing neuro-
muscular block; however, without reversal, waiting for a
spontaneous recovery may be time-consuming and can po-
tentially prolong the surgery. Before the introduction of
sugammadex into clinical practice, neuromuscular block
was routinely antagonized with neostigmine. This agent
inactivates acetylcholinesterase, which is responsible for
breakdown of acetylcholine and for displacing NMBAs to
acetylcholine from the nicotinic receptors. Because NMBAs
have a longer duration of action than cholinesterase inhibi-
tors, there is a risk of recurarization. This explains why an-
tagonism of intense blockade may be inefficient after
neostigmine administration. Neostigmine is also associated
with an increased risk for muscarinergic side effects, and
parasympatholytic anticholinergic drugs such as atropine or
glycopyrrolate need to be added. Another inconvenience is
its substantial variability of action [12].
Sugammadex has been suggested as a superior alterna-
tive. It is a modified γ-cyclodextrin specifically developed
for rapid reversal of a rocuronium- or vecuronium-
induced neuromuscular blockade achieved by forming a
stable and inactive complex and completely encapsulating
these agents. Up to 90 % of the sugammadex dose is ex-
creted within 24 h. Overall, 96 % of the dose is excreted in
the urine, of which at least 95 % could be attributed to un-
changed sugammadex. Administration of sugammadex to
healthy volunteers resulted in increased renal elimination
of rocuronium in complex with sugammadex. This results
in reducing the amount of NMBAs available to bind to
nicotinic receptors in the neuromuscular junction and in
the reversal of neuromuscular blockade. This particular
mechanism allows safe and effective antagonizing that can
be applied at any time during the neuromuscular block by
increasing doses of sugammadex. It is also devoid of the
risks of neostigmine and has better efficacy at reversal. A
phase III, active-controlled, randomized study proved that,
compared with neostigmine, sugammadex provides sig-
nificantly faster reversal of a deep rocuronium-induced
neuromuscular blockade [13]. In our patient, sugammadex
was administered at a TOF count of 0. The time to recov-
ery of the TOF ratio to 0.9 was 5 minutes, which allowed
IFNM to be conducted. Sugammadex was given in a 4
mg∙kg−1 dose. Fabregat et al. reported two patients [14] in
whom the sugammadex dosage was seemingly lower than
the one we used. Rocuronium-induced neuromuscular
block was reversed with sugammadex 0.22 mg∙kg−1 when
the TOF ratio was 0.14 in the first patient, and with
sugammadex 2 mg∙kg−1 during intense block (posttetanic
count = 0) in the second patient. The times to recovery of
the TOF ratio to 0.9 were 5 minutes and 6 minutes, 15
seconds, respectively.
We chose to completely reverse neuromuscular block
using sugammadex 4 mg∙kg−1 for different reasons. The
use of IFNM alone does not guarantee preservation of fa-
cial nerve function. An important factor is the experience
of the surgery team. The surgery was done by experienced
surgeons who are known to reach the facial nerve very
early with a significantly shorter interval between skin in-
cision and facial nerve identification. This explains why
sugammadex was administered earlier in the surgery at a
deeper level of blockade. In addition, the nerve in such
cases is chronically compressed by the tumor and may be
more sensitive to the effects of neuromuscular blockade.
Conclusions
Because of the importance of the facial nerve, its preser-
vation is a central goal of parotid surgery. Rapid reversal
Bensghir et al. Journal of Medical Case Reports  (2016) 10:187 Page 3 of 4
of rocuronium-induced neuromuscular block by sugam-
madex, coupled with the analysis of neuromuscular
blockade with the TOF method and IFNM, ensured the
preservation of neuromuscular function and created op-
timal conditions for the surgical team in this case.
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